clazakizumab clazakizumab clazakizumab (formerly ald518 and bms-945429), an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6. clazakizumab was developed by bristol myers squib and alder biopharmaceuticals. a preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect. clazakizumabmonoclonal antibodytypewhole antibodysourcehumanizedtargetil6clinical dataother namesald518, bms-945429routes ofadministrationinfusionatc codenonelegal statuslegal status investigational identifierscas number1236278-28-6chemspidernoneunii4s38z8ra9okeggd10312chemical and physical dataformulac6426h9972n1724o2032s42molar mass145239.02 g·mol−1